Compliance with Ethical Standards
Disclosure: The preparation of this review was
not supported by any external funding.
Conflicts of interest: Young-A Heo is a salaried employee of Adis
International Ltd/Springer Nature, is responsible for the article
content and declares no relevant conflicts of interest.
Additional information about this
Adis Drug Review can be found here
Subcutaneous insulin degludec/liraglutide
(Xultophy™) is a titratable, fixed-ratio combination of a long-acting
insulin analogue and a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that
is approved in several countries, including in the USA and those in the EU for
the treatment of type 2 diabetes (T2D) as add-on therapy. In clinical and
real-world studies in insulin-naïve or -experienced adults with inadequately
controlled T2D, once-daily insulin degludec/liraglutide as add-on therapy to
oral antidiabetic drugs consistently provided effective and durable glycaemic
control, and delayed the time to treatment intensification. It also reduced the
risk of hypoglycaemia and bodyweight gain compared with basal or basal-bolus
insulin therapy. Insulin degludec/liraglutide is generally well
tolerated and offers the convenience of once-daily administration of two injectable antidiabetic drugs.